代謝相關的共同研究及授權契約:2019年～2025年

代謝研究和授權協議提供了前所未有的機會，可以全面了解世界領先的生物製藥公司的代謝機會。

本報告已全面修訂和更新，提供 2019 年至 2025 年 576 項代謝相關交易的詳細資訊。

此報告提供雙方宣布的交易付款條款。這些數據為付款條款和其他貿易條款提供了有用的見解。

了解潛在合作夥伴談判交易條款的彈性可以為談判過程提供重要的見解，讓您了解談判條款時會發生什麼。許多小型企業可能會想要詳細的付款條款，但當涉及到如何產生付款以及如何轉移權利時，細節決定成敗。

本報告提供了當前協議交易和合作資料庫中記錄的自 2019 年以來宣布的合作和許可協議的綜合列表，包括可用的財務條款，並包含公司及其合作夥伴向 SEC 提交的實際許可協議文件的在線副本鏈接。

報告的第一章提供了代謝貿易和商業趨勢的快照。第 1 章對報告進行了介紹，第 2 章分析了 Metabolic 的交易趨勢。

第 3 章介紹了代謝空間中完成的交易的財務條款以及發展階段。交易按標題價值、預付款、里程碑付款和特許費率列出並分為幾個部分。

第 4 章回顧了在代謝交易中最活躍的 25 家生物製藥公司。對於美國證券交易委員會已公開宣布協議的案件，可以透過這些連結在當前協議交易和聯盟資料庫中線上存取該協議。

第 5 章對 2019 年以來簽署和宣布的代謝相關交易進行了全面深入的回顧，並提供合約文件。每個交易標題都透過網路連結連結到實際合約文件的線上版本，以便在需要時輕鬆存取每個合約文件。

第 6 章提供了與代謝相關的病例的綜合目錄，按治療目標列出。

該報告還包含大量圖表和圖形，說明了自 2019 年以來與代謝相關的病例趨勢和活動。

此外，我們還提供按公司 A-Z 和技術類型組織的綜合貿易目錄。每個交易標題都提供了一個指向交易記錄在線版本的網絡鏈接，並在可用的情況下提供合同文件，從而可以輕鬆、按需訪問每個交易文件。

主要優點

代謝相關的研究合作和授權協議為讀者提供了以下主要好處：

• 了解 2019 年及以後的合約趨勢
• 瀏覽代謝合作與許可機會
• 基準分析 - 確定交易的市場價值
• 財務條款 – 預付款、里程碑付款、特許權使用費
• 依公司 A-Z、治療目標、技術類型劃分的交易目錄
• 大額交易金額
• 最活躍的交易者
• 確定每筆交易的資產和條款
• 查閱合約文件－洞察交易結構
• 盡職調查 - 評估擬議交易條款對合作夥伴公司的適用性。
• 節省數百小時的研究時間

研究範圍

• 代謝研究合作與許可協議旨在更深入地了解全球領先生物製藥公司簽署的代謝趨勢和交易結構。

回報內容

• 生物製藥產業代謝相關交易趨勢
• 合作與授權協議架構概述
• 涵蓋藥品和生物技術的代謝相關交易記錄目錄
• 代謝相關領域的重大交易
• 最活躍的代謝許可交易制定者

目錄

摘要整理

第1章 簡介

第2章 代謝相關的交易趨勢

• 簡介
• 多年的代謝相關的聯盟
• 各交易類型的代謝聯盟
• 各業界的代謝相關的聯盟
• 各開發階段的代謝相關的聯盟
• 各技術類型的代謝相關的聯盟
• 各治療適應症的代謝相關的聯盟

第3章 代謝相關的聯盟的金融交易條件

• 簡介
• 公開代謝相關的聯盟相關財務條件
• 代謝合作夥伴的標題價值
• 代謝相關的交易預付款
• 代謝相關的交易的里程金
• 代謝權利金費率

第4章 主要代謝相關的交易和交易負責人

• 簡介
• 最活躍的代謝夥伴
• 最活躍的代謝交易者名單
• 各價值排名的頂級代謝交易

第5章 代謝契約文件名錄

• 簡介
• 已簽約的代謝聯盟交易

第6章 按治療標的代謝相關的交易

• 簡介
• 按治療標的代謝相關的交易
• 交易名錄
• 交易目錄 - 新陳代謝交易（按公司劃分）（2019-2025 年）
• 交易目錄 - 按技術類型劃分的代謝交易（2019-2025 年）
• 定義交易類型
• 關於 Biopharma Research Ltd
• 當前合作夥伴關係
• 當前合約
• Current Partnering 的最新報告標題

Metabolic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the metabolic deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 576 metabolic deals from 2019 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of metabolic dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in metabolic dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the metabolic field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in metabolic dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of metabolic deals signed and announced since 2019 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of metabolic deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in metabolic deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Metabolic Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse metabolic collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Metabolic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of metabolic trends and structure of deals entered into by leading biopharma companies worldwide.

Metabolic Collaboration and Licensing Deals includes:

• Trends in metabolic dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of metabolic deal records covering pharmaceutical and biotechnology
• The leading metabolic deals by value
• Most active metabolic licensing dealmakers

In Metabolic Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Metabolic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in metabolic dealmaking

• 2.1. Introduction
• 2.2. Metabolic partnering over the years
• 2.3. Metabolic partnering by deal type
• 2.4. Metabolic partnering by industry sector
• 2.5. Metabolic partnering by stage of development
• 2.6. Metabolic partnering by technology type
• 2.7. Metabolic partnering by therapeutic indication

Chapter 3 - Financial deal terms for metabolic partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for metabolic partnering
• 3.3. Metabolic partnering headline values
• 3.4. Metabolic deal upfront payments
• 3.5. Metabolic deal milestone payments
• 3.6. Metabolic royalty rates

Chapter 4 - Leading metabolic deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in metabolic partnering
• 4.3. List of most active dealmakers in metabolic
• 4.4. Top metabolic deals by value

Chapter 5 - Metabolic contract document directory

• 5.1. Introduction
• 5.2. Metabolic partnering deals where contract document available

Chapter 6 - Metabolic dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by metabolic therapeutic target
• Deal directory
• Deal directory - Metabolic deals by company A-Z 2019 to 2025
• Deal directory - Metabolic deals by technology type 2019 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Metabolic partnering since 2019
• Figure 2: Metabolic partnering by deal type since 2019
• Figure 3: Metabolic partnering by industry sector since 2019
• Figure 4: Metabolic partnering by stage of development since 2019
• Figure 5: Metabolic partnering by technology type since 2019
• Figure 6: Metabolic partnering by indication since 2019
• Figure 7: Metabolic deals with a headline value
• Figure 8: Metabolic deals with upfront payment values
• Figure 9: Metabolic deals with milestone payment
• Figure 10: Metabolic deals with royalty rates
• Figure 11: Active metabolic dealmaking activity since 2019
• Figure 12: Top metabolic deals by value since 2019